TNF Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based Payments (Tables)

Share-based Payments (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Stock Options Activity

The following table summarizes the option activities for the three months ended March 31, 2018:

										Weighted
						Weighted				Average
						Average				Remaining				Aggregate
		Number of				Exercise				Contractual				Intrinsic
		Shares				Price				Term (years)				Value
*Balance at December 31, 2017*			255,000			$	4.25				2.02			$	-
Granted			-				-				-				-
Exercised			-				-				-				-
Forfeited			-				-				-				-
Canceled/Expired			-				-				-				-
*Balance at March 31, 2018*			255,000			$	4.25				1.78			$	-
*Exercisable as of March 31, 2018*			250,334			$	4.27				1.75			$	-

Schedule of Non Vested Share Activity

A summary of the Company’s non-vested shares as of March 31, 2018 and the changes during the three months then ended are as follows:

						Weighted
						Average Grant
Non-Vested Shares		Shares				Date Fair Value
Non-vested at December 31, 2017			4,666			$	2.36
Granted			-				-
Vested			-				-
Forfeited			-				-
Non-vested at March 31, 2018			4,666			$	2.36

Summary of Warrant Activity

The table below summarizes the warrant activity for the three months ended March 31, 2018:

						Weighted				Average
						Average				Remaining
		Number of				Exercise				Contractual
		Warrants				Price				Term (years)
*Balance at December 31, 2017*			49,490,571			$	0.22				4.95
Granted			-				-				-
Exercised			(30,492,070	)			0.19				-
Forfeited			-				-				-
Canceled/Expired			-				-				-
*Balance at March 31, 2018*			18,998,501			$	0.28				4.68
*Exercisable as of March 31, 2018*			18,998,501			$	0.28				4.68